The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 162:1744-1746, September 2005
doi: 10.1176/appi.ajp.162.9.1744
© 2005 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Graham, K. A.
* Articles by Perkins, D. O.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Graham, K. A.
* Articles by Perkins, D. O.
Related Collections
* Neurotransmitters
* Bipolar Disorder
* Atypical Neuroleptics
* Schizophrenia Spectrum Disorders
* Other Somatic Therapy

Brief Report

Double-Blind, Placebo-Controlled Investigation of Amantadine for Weight Loss in Subjects Who Gained Weight With Olanzapine

Karen A. Graham, M.Sc., M.D., Hongbin Gu, Ph.D., Jeffrey A. Lieberman, M.D., Joyce B. Harp, M.D., and Diana O. Perkins, M.D., M.P.H.

OBJECTIVE: This study sought to determine if amantadine affects weight gain in psychiatric patients taking olanzapine. METHOD: Twenty-one adults who had gained at least 5 lb with olanzapine were randomly assigned to receive amantadine (N=12) or placebo (N=9) in addition to olanzapine. The length of time taking olanzapine ranged from 1 to 44 months. Body mass index, psychiatric status, and fasting blood levels were assessed at baseline and 12 weeks. RESULTS: Significantly fewer subjects taking amantadine gained weight, with a mean change in body mass index of –0.07 kg/m2 for the amantadine group and 1.24 kg/m2 for the placebo group. This effect remained significant when the authors controlled for baseline body mass index and length of olanzapine treatment. No changes in fasting glucose, insulin, leptin, prolactin, and lipid levels were seen. Positive and Negative Syndrome Scale scores remained stable. CONCLUSIONS: Amantadine induced weight stabilization in subjects taking olanzapine and was well tolerated.




This article has been cited by other articles:


Home page
FocusHome page
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Focus, January 1, 2008; 6(2): 246 - 253.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
D. J. Klein, E. M. Cottingham, M. Sorter, B. A. Barton, and J. A. Morrison
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents
Am J Psychiatry, December 1, 2006; 163(12): 2072 - 2079.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Am J Psychiatry, October 1, 2006; 163(10): 1697 - 1704.
[Full Text] [PDF]


Home page
Psychiatr. NewsHome page
J. Arehart-Treichel
Drug Fights Weight Gain Induced by Antipsychotics
Psychiatr News, October 7, 2005; 40(19): 27 - 27.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org